Skip to content

A Study Using L5 as a Risk Factor of Cardiovascular (CV) Disease in Chronic Renal and Dialytic Patients

L5 as a Risk Factor of Cardiovascular Disease in Chronic Kidney Disease and Dialysis Patients

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01236820
Acronym
L5
Enrollment
48
Registered
2010-11-09
Start date
2010-09-30
Completion date
Unknown
Last updated
2010-11-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiovascular Disease, Chronic Kidney Disease Patients, Hemodialytic Patients, High L5 Level, High LDL Level

Keywords

L5, LDL, Cardiovascular disease, Chronic kidney disease, Hemodialysis

Brief summary

The purpose of this study is to determine whether L5, one of the Low Density Lipoproteins, is an effective predicting factor for cardiovascular disease in chronic renal and hemodialytic patients.

Detailed description

Cardiovascular disease (CVD) is the most important cause of death of chronic kidney disease (CKD) and hemodialysis (HD) patients. Low Density Lipoprotein (LDL) is an essential indicator of CVD.The higher the plasma LDL level, the higher the risk of CVD. LDL is a heterogenous substance composed of different mass and size. Oxidized LDL (oxLDL) is the oxidation product of LDL and is the most important component of LDL associated with CVD. The oxLDL is mostly trapped within tissue and not easily to be detected from blood. L5 iw a kind of electronegative LDL and is associated with CVD in smokers and diabetic patients, even if these patients have normal plasma LDL. Uremia patients have lipid profile different from that of general people,while HD Patients have lower LDL and CKD patients have LDL higher than that of general population. Thus LDL plasma level cannot fully explain the high risk of CVD in CKD and HD patients. As patients with normal LDL but high L5 are prone to have CVD, we suspect there might be association of L5 with CVD in both CKD and HD patients.

Interventions

None listed

Sponsors

China Medical University Hospital
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
20 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* clinical diagnosis of CKD * clinical diagnosis of HD

Exclusion criteria

* N/A

Countries

Taiwan

Contacts

Primary ContactChiz-Tzung Chang, Ph.D.
D19863@mail.cmuh.org.tw886-4-22052121
Backup ContactChiu-Ching Huang, MD
cch@mail.cmuh.org.tw886-4-22052121

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026